Alzamend Neuro (ALZN) vs Pulmatrix (PULM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alzamend Neuro is the larger company by market cap ($6.6 million vs $5.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | PULM |
|---|---|---|
| Share price | $1.36 | $1.45 |
| Market cap | $6.56M | $5.30M |
| 1-day change | +1.49% | -5.05% |
| EPS (TTM) | $-2.30 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $5.24 |
| 52-week low | $0.84 | $1.16 |
| Distance from 52-week high | -49.25% | -72.30% |
| Analyst consensus | none | — |
| Avg. price target upside | +1811.76% | — |
| Average volume | 88.67K | 24.09K |
| Shares outstanding | 4.83M | 3.65M |
| Employees | 4 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Pulmatrix
PULM stock →Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ALZN vs PULM FAQ
Which is bigger, Alzamend Neuro or Pulmatrix?
Alzamend Neuro (ALZN) is larger, with a market capitalization of $6.56M compared with $5.30M for Pulmatrix (PULM).
Are Alzamend Neuro and Pulmatrix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.